A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial

ConclusionSorafenib 200  mg bid 5 days-on/2 days-off + everolimus 5 mg qd continuous was selected for an additional arm of EVESOR trial to evaluate whether this simulated schedule is associated with higher clinical benefit.Trial registrationClinicalTrials.gov Identifier: NCT01932177.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research